Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI

SCI 后高于替代睾酮加非那雄胺的治疗

基本信息

  • 批准号:
    10251014
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-05-01 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: The Institute of Medicine has indicated that short-term, small scale randomized clinical trials (RCTs) should be conducted to establish the efficacy of testosterone replacement therapy (TRT) as a strategy to enhance muscular strength and reduce disability in clinical populations of hypogonadal men. Men with spinal cord injury (SCI) experience a high prevalence of hypogonadism which influences the neural, muscular, skeletal, and body composition deficits that occur after injury. In this regard, a single retrospective analysis has reported that TRT improved motor function in hypogonadal men with incomplete SCI. However, only one small prospective (open label) clinical trial has evaluated the safety/efficacy of TRT in men with SCI. This study reported that low- dose TRT improved lower extremity lean mass and reduced risk of sudden cardiac death in men with motor complete SCI, demonstrating that testosterone (T) safely improves lean mass even in the absence of voluntary muscle activity. However, body composition and bone mineral density (BMD) were unaltered in this study because these deficits respond only to higher-than-replacement T. Despite the potential benefits of TRT, clinical concern exists regarding the safety of this therapy, with increased hematocrit (which is rarely detrimental) and prostate enlargement being the only health risks proven by meta-analysis. Interestingly, the 5�-reduction of T to dihydrotestosterone (DHT) mediates prostate enlargement, but this conversion is not required for the benefits of TRT. As evidence pharmacologic 5�-reductase inhibition (via finasteride) ablates prostate enlargement in neurologically healthy hypogonadal men receiving higher-than-replacement T, without inhibiting the substantial musculoskeletal and lipolytic benefits of this treatment. However, the safety and efficacy of this novel combination therapy remains to be determined in men with chronic motor incomplete SCI. For this double-blind placebo-controlled RCT, hypogonadal men >18 years of age with chronic motor incomplete SCI (AIS C/D) who present with ambulatory dysfunction (0.20m/s - 0.80m/s on 10m walk test) will receive slightly higher-than-replacement T (125mg/week, i.m.) plus finasteride (5mg/day, p.o.) in FDA approved doses or vehicle/placebo for 12 months. We will assess: BMD and body composition via DXA, thigh muscle cross-sectional area (CSA) via MRI, maximal knee extensor (KE) torque via dynamometry, KE muscle activation via twitch interpolation, circulating markers of bone turnover and metabolic health, and safety measures including prostate health, hematocrit, and other putative health risks associated with TRT. Our primary hypotheses are that slightly higher-than-replacement T plus finasteride will safely 1) regenerate BMD in this population via antiresorptive actions, 2) enhance muscle CSA and improve neuromuscular force production, and 3) improve body composition. In order to test these hypotheses, the following Specific Aims will be evaluated: AIM 1: Evaluate the effects of 12 months of slightly higher-than-replacement T plus finasteride on bone mineral characteristics and bone turnover in hypogonadal men with motor incomplete SCI. AIM 2: Determine the effects of slightly higher-than-replacement T plus finasteride on the recovery of muscle integrity and neuromuscular force production in hypogonadal men with motor incomplete SCI. Exploratory AIM 3: Examine the effects of slightly higher-than-replacement T plus finasteride on body composition and the pathophysiology underlying metabolic syndrome in men with motor incomplete SCI. This proposal will provide the first-ever prospective clinical evidence evaluating whether higher-than- replacement T plus finasteride safely regenerates musculoskeletal integrity, enhances neuromuscular function, and improves body composition and metabolic health in hypogonadal men with motor incomplete SCI. These findings will benefit Veterans with SCI who experience musculoskeletal impairments and may provide the VA with a novel cost-effective therapy able to improve musculoskeletal and metabolic health in this population.
产品说明: 医学研究所指出,应进行短期、小规模随机临床试验(RCT),以确定睾酮替代疗法(TRT)作为一种增强肌肉力量和减少性腺功能减退男性临床人群残疾的策略的疗效。男性脊髓损伤(SCI)患者的性腺功能减退发生率很高,这会影响损伤后发生的神经、肌肉、骨骼和身体成分缺陷。在这方面,一项回顾性分析报告称,TRT改善了性腺功能减退的不完全SCI男性的运动功能。然而,只有一项小型前瞻性(开放标签)临床试验评价了TRT在SCI男性中的安全性/有效性。该研究报告,低剂量TRT改善了运动性完全性SCI男性的下肢瘦体重,降低了心源性猝死的风险,表明睾酮(T)即使在无自主肌肉活动的情况下也能安全改善瘦体重。然而,在这项研究中,身体成分和骨矿物质密度(BMD)没有改变,因为这些缺陷只对高于替代T的反应。尽管TRT具有潜在的益处,但仍存在关于该疗法安全性的临床问题,荟萃分析证实,红细胞压积增加(很少有害)和前列腺肥大是唯一的健康风险。有趣的是,5 β-还原T为双氢睾酮(DHT)介导前列腺肥大,但这种转化不是TRT获益所必需的。作为证据,药理学5 β-还原酶抑制剂(通过finaldade)消除了接受高于替代T的神经健康性腺功能减退男性的前列腺肥大,而不会抑制这种治疗的实质性肌肉骨骼和脂解益处。然而,这种新的联合治疗的安全性和有效性仍有待确定的男性慢性运动不完全性脊髓损伤。 对于这项双盲安慰剂对照RCT,年龄>18岁的性腺功能减退男性慢性运动不完全性SCI(AIS C/D),表现为行走功能障碍(10米步行试验为0.20 m/s -0.80 m/s),将接受略高于替代T(125 mg/周,i.m.)加非那肽(5 mg/天,p.o.)以FDA批准的剂量或溶剂/安慰剂给药12个月。我们将评估:通过DXA测定BMD和身体成分,通过MRI测定大腿肌肉横截面积(CSA),通过测力计测定最大膝伸肌(KE)扭矩,通过抽搐插值测定KE肌肉激活,骨转换和代谢健康的循环标志物,以及安全性指标,包括前列腺健康、血细胞比容和其他与TRT相关的推定健康风险。我们的主要假设是,略高于替代的T+芬那肽将安全地1)通过抗吸收作用再生该人群的BMD,2)增强肌肉CSA并改善神经肌肉力量的产生,3)改善身体组成。为了检验这些假设,将评价以下特定目的:目的1:评价12个月略高于替代的T+非那肽对患有运动不完全性SCI的性腺功能减退男性的骨矿物质特征和骨转换的影响。 目标2:确定略高于替代的T加非那肽对运动不完全性脊髓损伤性腺功能减退男性的肌肉完整性和神经肌肉力量产生的恢复的影响。 探索性目标3:检查略高于替代的T加芬那肽对运动不完全性SCI男性的身体成分和代谢综合征的病理生理学的影响。 该提案将提供有史以来第一个前瞻性临床证据,以评估高于替代T+芬氟拉明是否安全地再生肌肉骨骼完整性,增强神经肌肉功能,并改善性腺功能减退男性运动不完全性脊髓损伤的身体组成和代谢健康。这些发现将使经历肌肉骨骼损伤的SCI退伍军人受益,并可能为VA提供一种新的具有成本效益的治疗方法,能够改善该人群的肌肉骨骼和代谢健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joshua F. Yarrow其他文献

Joshua F. Yarrow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joshua F. Yarrow', 18)}}的其他基金

ShEEP Request for High Resolution Desktop MicroCT System
SheEEP 请求高分辨率桌面 MicroCT 系统
  • 批准号:
    10538047
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development and Validation of a Rodent FES Bicycle System
啮齿动物 FES 自行车系统的开发和验证
  • 批准号:
    10367994
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Development and Validation of a Rodent FES Bicycle System
啮齿动物 FES 自行车系统的开发和验证
  • 批准号:
    10554098
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Locomotor Training with Anabolic Adjuvants for Musculoskeletal Recovery After SCI
使用合成代谢佐剂进行运动训练以促进 SCI 后的肌肉骨骼恢复
  • 批准号:
    9505304
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Locomotor Training with Anabolic Adjuvants for Musculoskeletal Recovery After SCI
使用合成代谢佐剂进行运动训练以促进 SCI 后的肌肉骨骼恢复
  • 批准号:
    10407486
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Locomotor Training with Anabolic Adjuvants for Musculoskeletal Recovery After SCI
使用合成代谢佐剂进行运动训练以促进 SCI 后的肌肉骨骼恢复
  • 批准号:
    10840774
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Role Of Bone Blood Flow In Bone Loss Following SCI
骨血流量在 SCI 后骨质流失中的作用
  • 批准号:
    9236938
  • 财政年份:
    2016
  • 资助金额:
    --
  • 项目类别:
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
SCI 后高于替代睾酮加非那雄胺的治疗
  • 批准号:
    9901435
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
In Vivo Microcomputed Tomography (uCT) Acquisition
体内微计算机断层扫描 (uCT) 采集
  • 批准号:
    8948248
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI
SCI 后高于替代睾酮加非那雄胺的治疗
  • 批准号:
    10275496
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:

相似海外基金

REU Site: Design, Create, and Innovate 3-Dimensional User Interfaces to Improve Human Sensory and Motor Performance in Virtual Environments (HUMANS MOVE)
REU 网站:设计、创建和创新 3 维用户界面,以提高虚拟环境中的人类感官和运动表现 (HUMANS MOVE)
  • 批准号:
    2349771
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
CAREER: Atomic-level understanding of stability and transition kinetics of 3-dimensional interfaces under irradiation
职业:对辐照下 3 维界面的稳定性和转变动力学的原子水平理解
  • 批准号:
    2340085
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Artificial fabrication of 3-dimensional noncollinear magnetic order and magnetization manipulation by spin torque
三维非共线磁序的人工制造和自旋转矩磁化操纵
  • 批准号:
    23H00232
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Understanding of 3-dimensional seismic behavior of RC frame high-speed railway/highway viaducts using FE analysis
使用有限元分析了解 RC 框架高速铁路/公路高架桥的 3 维抗震性能
  • 批准号:
    23H01489
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Modernization of 3-dimensional printing capabilities at the Aquatic Germplasm and Genetic Resource Center
水产种质和遗传资源中心 3 维打印能力的现代化
  • 批准号:
    10736961
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The 3-dimensional nest of the honey bee: organization, development, and impact on colony function
蜜蜂的 3 维巢穴:组织、发育及其对蜂群功能的影响
  • 批准号:
    2216835
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Research on high-density 3-dimensional polymer optical waveguide device for photonics-electronics convergence
光电子融合高密度三维聚合物光波导器件研究
  • 批准号:
    23H01882
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Scaff-Net: 3 Dimensional multiphoton polymerisation printed scaffolds for medium throughput recording from stem cell derived human cortical networks.
Scaff-Net:3 维多光子聚合打印支架,用于从干细胞衍生的人类皮质网络进行中等通量记录。
  • 批准号:
    EP/X018385/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grant
3-dimensional prompt gamma imaging for online proton beam dose verification
用于在线质子束剂量验证的 3 维瞬发伽马成像
  • 批准号:
    10635210
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Equipment: MRI: Track 1 Acquisition of a 3-Dimensional Nanolithography Instrument
设备:MRI:轨道 1 获取 3 维纳米光刻仪器
  • 批准号:
    2320636
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了